Pfizer plans to submit data to the Food and Drug Administration for a fourth Covid vaccine soon, and it is working on a vaccine that protects against all variants of the coronavirus, CEO Albert Bourla told CNBC on Friday.
“I think we’re going to submit significant breakthrough data on the need for a fourth dose to the FDA, and they have to come to their own conclusions, of course, and then the CDC as well. … Clearly there’s a need for an omicron environment to stimulate the immune response,” Bourla said in an interview on “Squawk Box.”
“We are making a vaccine that covers omicron and all the other variants. There are so many trials going on right now, and we will start reading a lot of them by the end of the month,” a- he continued later, adding that he’s optimistic based on the preliminary data he’s seen.
Bourla’s comments come exactly two years after Covid was declared a pandemic by the World Health Organization on March 11, 2020 and the global economy came to a standstill.
- Pandemic measures were put in place soon after, including mask mandates and travel restrictions, and then a major breakthrough came when Covid vaccines were developed and cleared for use.
- Since then, about 81.4% of the US population aged five or older has received at least one of the three vaccine doses authorized in the US by Pfizer, Moderna and Johnson & Johnson, according to the Centers for Disease Control and Prevention.
- Currently, daily Covid cases and deaths have dropped sharply since the peak in January this year due to the omicron wave. Several states have lifted mask mandates in schools and other public places.
- Companies such as Google and Apple called workers back to the office. Businesses, including restaurants, entertainment venues and more, have also come back to life.
Despite a semblance of a normal return, Bourla maintained that he remained vigilant in creating effective vaccines. “I think the biggest question for all of us is how do we stay ahead of the virus.”
He said Pfizer is working on developing a vaccine that prevents infection in addition to preventing hospitalizations and severe cases of the virus, adding that making durable vaccines is also a priority.
“We can’t have vaccines every five or six months,” Bourla said. “We need to be able to move as soon as possible.”